AbCellera Biologics Inc. (ABCL) Earnings Call Transcript
August 5, 2026
Earnings Call Speaker Segments
Thanks. Good day, everyone, and welcome to the earnings call for AbCellera's second quarter of 2026. I'm Tryn Stimart, and I serve as AbCellera's Chief Legal and Compliance Officer. Speaking today are Dr. Carl Hansen, our President and CEO, along with Andrew Booth, our Chief Financial Officer. On this call, we might discuss our strategic priorities and financial outlook, drawing on what we currently expect and in line with the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements carry a number of risks, uncertainties, and other factors that may lead actual results to differ materially from what we describe. For a more detailed discussion of these risks, please look at the Risk Factors section in our most recent Form 10-K and subsequent 10-Q filings with the SEC. AbCellera undertakes no obligation to update any forward-looking statements to reflect events or circumstances occurring after today's date. Today's presentation, along with our earnings press release and our SEC filings, can be found on our Investor Relations website. What we share about our pipeline is meant for the investment community and is not promotional. As we move to our prepared remarks, please be aware that this call is being recorded and will be available for replay on our investor relations website, and that every dollar figure mentioned during the call is in U.S. dollars. Following our prepared remarks, we will open the lines for questions and answers. Now I'll hand the call over to Carl.
Thank you, Tryn, and I appreciate all of you being here with us today. The single most significant data announcement we anticipate this year involves the topline findings for ABCL635 when used to treat moderate to severe hot flashes tied to menopause. During the prior quarter, we presented interim phase I results demonstrating strong and lasting target engagement among healthy male participants, which justified moving swiftly into a phase II trial involving post-menopausal women who experience moderate to severe hot flashes. Enrollment for that trial picked up speed throughout H1, and by June we had finished both recruitment and the first dosing of patients, coming in well ahead of our expected timeline. Given that, a topline data readout should arrive very shortly. Should those results prove favorable, we think ABCL635 will carry substantially reduced risk. As we mentioned on our previous call, preparations for subsequent steps have been underway, and those would encompass late-stage clinical development for moderate to severe VMS linked to menopause, plus clinical trials assessing ABCL635 as a treatment for VMS connected to cancer therapy. Shifting to the wider portfolio, ABCL688 and ABCL386 keep moving forward with IND-enabling work, and we anticipate both reaching phase I/II studies during 2027; additional details about these programs will be shared once they begin clinical testing. Dosing has been completed in our phase I trial of ABCL575, which remains on schedule for a Q4 readout. As we've said before, our intention is to finish phase I studies, and at present we have no plans for development beyond phase I. Lastly, I had earlier set a goal of advancing one more program into IND-enabling activities during this year's first half. We did miss that timeline, but solid progress is being made, and I have strong confidence in the productivity and innovation coming out of discovery. The biggest public disclosures since our previous earnings call concern business development tied to our T-cell engager platform. To refresh everyone, our work on TCEs began 5 years ago, and we've invested substantially in the platform since that time. The starting hypothesis for our efforts was that a wider variety of CD3 binders would matter for engineering TCEs that have better therapeutic characteristics. Our in-house work so far has confirmed that, yet it has also shown that having diverse CD3 binders by itself does not get the job done. What we understand now is that achieving repeated success at generating optimal TCEs demands a full toolkit spanning binders, technologies, assays, models, and biological insight. So our platform today features varied panels of CD3-targeting antibodies, together with proprietary panels of costimulatory antibodies that enhance and fine-tune how TCEs function, scalable protein engineering workflows capable of producing a broad range of binder combinations and formats, scalable in vitro assays for evaluating TCE function and development attributes, expertise in translating between in vitro assays and in vivo models spanning multiple targets, and increasingly, a linkage between TCE properties and clinical data from third parties. Taken together, we think this yields a highly enabled platform for creating multi-specific TCEs with wide applications spanning oncology and autoimmunity. So, even as we use this capability to push our internal programs forward, we see it as a major platform for strategic partnerships too. Our first big TCE collaboration, with AbbVie, was announced last year. And on top of that, we've just signed two fresh TCE collaborations — one with Vertex, one with Jazz. Those two deals bring more than $110 million in upfront cash onto our balance sheet, and they could be worth a lot more down the line through downstream payments and tiered royalties on net sales. Last week, we announced our newest collaboration, this one with Vertex, centered on TCEs for autoimmune diseases and other conditions. Per the deal terms, AbCellera gets $28 million in upfront payments, could receive potential downstream payments and tiered royalties on net sales, and holds a potential option to carry out process development and clinical manufacturing. Back in June, we also announced a collaboration with Jazz Pharmaceuticals covering three confirmed discovery programs, with $84 million in total near-term upfront payments. For the first two programs, we've already received $56 million in upfront payments, and we'll get another $28 million for the third program, which kicks off within the next 12 months. Under that agreement, AbCellera can also receive over $2 billion in potential downstream payments, plus mid-single-digits to low double-digit tiered royalties on net sales. The deal further includes a mutual option for two more discovery programs on the same financial terms, and a mutual option for AbCellera to take on certain R&D enabling activities and clinical manufacturing. Including all five programs, the total potential deal value would exceed $4 billion. We think this ranks among the largest TCE discovery deals reported so far. Before I turn things over to Andrew, I'm happy to welcome Dr. Victor Sandor and Dr. Lynn Seely as new Independent Directors on AbCellera's board. Dr. Sandor and Dr. Seely are seasoned biopharmaceutical executives whose proven, complementary expertise spans development in oncology, women's health, immunology, and endocrinology. Lynn and Victor bring deep expertise and development experience that will serve us well as we build our portfolio and our company. With that, I'll hand it over to Andrew to discuss our financials. Andrew?
Thanks, Carl. Like Carl mentioned, AbCellera remains in a solid cash position, holding more than $565 million in cash and equivalents, along with about $110 million in committed government funding that's available to carry out our strategy. We're still moving forward with our plans, concentrating on internal programs and making use of our investments in process development and clinical manufacturing. When it comes to revenue and expenses, revenue during the quarter came in at roughly $4 million, versus total revenue of about $17 million in the equivalent quarter of 2025. Research fees made up the bulk of this quarter's revenue. R&D expenses for the quarter totaled approximately $46 million, which is roughly $7 million higher than a year ago. That cost reflects our emphasis on putting money into internal programs. On the SG&A side, expenses came to approximately $14 million, down from $22 million last year. The significant drop in SG&A is tied to the wrapping up of our intellectual property litigation matter and to team changes that followed our shift in focus toward the internal pipeline. Now for earnings: we're reporting a net loss of about $55 million for the second quarter of 2026, against a loss of roughly $35 million during the same period a year earlier. On a per-share basis, that comes to a loss of $0.18, both basic and diluted. Switching to cash: overall, we ended the quarter holding $567 million in total cash and marketable securities, which represents a $6 million rise in total cash across the first half of 2026. Cash used by operating activities during the first half came to approximately $8 million. Within that operating cash flow is a $56 million receipt tied to the upfront payments from our TCE deal with Jazz. That piece of the upfront payments from the Jazz partnership came in during the quarter. Leaving aside marketable securities, investment activities so far this year included roughly $6 million in capital expenditures, offset by $7 million in government grants we received. As part of our treasury strategy, $420 million sits in short-term marketable securities. Our investment activities this quarter included putting $15 million into those holdings. As a reminder, we've secured commitments to fund advancement of our internal pipeline from the Government of Canada Strategic Innovation Fund and the Government of British Columbia; that available capital isn't reflected on our balance sheet. With more than $565 million in cash and equivalents plus the untapped portion of our secured government funding, we have over $675 million in available liquidity to carry out our strategy. Beyond that, we hold additional available liquidity through our ownership of the other Vancouver lab-based office building, as well as our GMP facility; when it comes to overall company expenditures, our capital needs are quite manageable. We remain confident that our liquidity is enough to fund at least the next three years of pipeline investments. With that, we're happy to take your questions. Operator?
Good afternoon, and thanks a lot for taking my question. First, regarding the VMS data that's coming up, what would you consider a clinically meaningful improvement in VMS severity, just within that context? I believe there's a three-point ordinal scale being used to assess severity; and then, will threshold analyses for the VMS frequency data be included with top line, such as the proportion of patients achieving a 90% or 100% reduction in frequency? Just wondering whether that will be part of the top line; then I have a follow-up as well.
Steve, this is Carl. Thanks for the question. First, regarding the readout that's coming up, which we're clearly very excited about, our view is that success means a clean safety profile, and everything we've seen so far through phase I has been entirely consistent with that, plus efficacy that tracks comparably to the two approved small molecules. On the frequency side, we're clearly looking for a response versus placebo on the order of 20% at least, which is roughly what you see with the small molecules. There's also a requirement that you achieve a reduction in frequency of at least two hot flashes per day, which we expect to meet under the same criteria. On the severity side, we expect that if we get the frequency, we'll track with severity and have numbers very comparable to the small molecules. I don't think we've communicated a definitive bar on that one, but historically, severity has been easier to hit than frequency, and we're really more focused on the frequency side right now.
Okay, thank you, Carl. You offered a few remarks, and you've brought this up previously regarding a possible use in cancer. I assume that would definitely include women dealing with breast cancer, though possibly men undergoing androgen deprivation therapy as well. It seemed as though you intended to explore launching a few phase II trials alongside the later-stage menopause program. Still, I'm wondering why you wouldn't go straight into phase III label-enabling studies for those cancer indications, considering what OASIS-4 showed with VEOZAH, and presuming you'll have favorable phase II results of your own and that dose selection would be made easier by that. I'd really like to hear your perspective on this.
Thank you, Steve. That's an excellent question. It's likely one better put to Sarah, our Chief Medical Officer, because she has clearly been the lead on the regulatory strategy. From what I understand, starting first in this patient population — which will clearly be quite different, since you're working with oncology patients — is the initial step prior to advancing to later-stage trials. We anticipate kicking that off fairly soon as we prepare for the bigger study on VMS tied to menopause. Naturally, some interval will exist between a readout and wrapping up the final trial and having everything arranged for that. We're sequencing it as fast as we can.
Hi there. I really appreciate you letting me ask something. I'd like to dig into differentiation when it comes to safety. The small molecules carry requirements for monitoring the liver. Assuming the data we're about to get from ABCL635 confirms — I should say reconfirms — a clean liver profile, could you discuss what your plans are for phase III regarding liver monitoring, so you can establish a definitive edge on that front? And separately, do you believe a clear safety edge would assist in capturing the first-line non-hormonal market? Thanks, and I have one more question after this.
Absolutely. I'll likely avoid going too far into the weeds here, given that data should arrive fairly soon, and afterward we'll have plenty of chances to address all of those questions. Just to touch on it briefly: as you noted, safety has been a major point of emphasis for us as a differentiator. Liver monitoring is required for both of the two small molecules; that's inconvenient, whether you look at it practically or from the patient's standpoint. Our view is that this is a property tied to how small molecules are metabolized, and one that an antibody ought not to share. Naturally, as we said on the last earnings call, everything we've seen thus far indicates no detectable rise in liver enzymes among any patients, so the thesis holds up, and we anticipate that will remain the case; as for how we approach this moving forward, that falls to Sarah, though my expectation is that we'll keep doing some monitoring of enzyme levels and confirm that this continues to hold. Honestly, scientifically speaking, I can't see any reason it wouldn't. Another item you left out regarding safety: a somnolence side effect has been linked to the Bayer molecule. In our view, that somnolence side effect stems from that molecule binding not only to NK3R but also to NK1R; our antibody is specific — completely specific — to NK3R, so we don't anticipate that showing up, and clearly, nothing of the sort has appeared in the data we've examined so far. That's one more thing we'll be highlighting. Beyond the convenience that comes with once-monthly dosing, we do believe better safety for a product such as this is paramount, and the data we've observed to this point leaves us very encouraged.
Excellent, thanks a lot. I just want to ask something quickly about those partnership deals you've closed with Vertex and Jazz. It looks like the emphasis there is on multi-specific T-cell engagers. I'm curious whether you could share roughly what share of your internal resources goes toward this TCE platform as opposed to the others, in particular the GPCR ion channel platform.
That's a wonderful question. Like I said during my prepared remarks, our TCE efforts have been going on for quite a while now. Over the past 5 years, we've been laying down several of the truly essential pieces needed to carry out these kinds of treatments, and throughout that process, we've gained substantial knowledge about what's required to win in this area. A great deal of that is behind us at this point. Today we run off a platform that's well established. Since that effort is finished, we now have additional capacity available to bring on more programs. My expectation is that our resource allocation toward TCE won't shift dramatically, though its direction will move away from establishing the groundwork, developing the know-how and the skill sets, and toward applying those skill sets, for both in-house programs and partner programs. It makes us very happy to watch that pay off and to have drawn in 2 outstanding partners, Vertex and Jazz, who place a premium on high innovation and are committed to advancing these into the clinic. One final thing regarding how TCEs stack up against, say, GPCRs and ion channels: I can't give you an exact figure, but I would say the GPCR and ion channel side sees considerably more effort. TCE has stood as one of the pipeline's strong pillars, and we anticipate it will remain so going forward.
Fantastic. Many thanks for that added detail.
Hi there, good afternoon; Josh here filling in for Steve. We appreciate you fielding our questions and congratulations on the advancement. Perhaps, continuing from that initial inquiry, with a focus on severity. When examining certain past fezolinetant and elinzanetant information, it seems fezolinetant might not truly demonstrate a statistically significant effect regarding severity at particular time points; elinzanetant appears, especially at subsequent time points and with larger doses, to have displayed this. I was hoping to hear your perspective on whether severity could be something tied to exposure and how you consider that alongside ABCL635's differentiation through the extended pathway.
That's an excellent question. I'm not certain precisely which data you're reviewing. Severity and frequency both matter as regulatory endpoints that must be achieved; that's the premise we're operating under, and we believe they align quite closely. At minimum, there is extensively documented information regarding dose escalation for fezolinetant, in which increasing the dose produced better efficacy, in both frequency and severity. Regarding severity, it appeared that this dose response persisted longer or leveled off afterward compared to frequency. I believe that fits with what you're describing, though I'd hesitate to speculate excessively about precisely how this will unfold. Regardless, we are eagerly anticipating the forthcoming data; we'll have that answer quite soon, and afterward we'll examine it more thoroughly.
Appreciate you fielding this.
Hello, this is Malcolm Hoffman, sitting in for Evan. We appreciate you addressing our query. When it comes to T-cell engagers for autoimmune conditions, the Vertex partnership is relevant. Even if you can't reveal which targets are involved, could you talk about the technical characteristics needed to achieve a therapeutic profile that's acceptable for these autoimmune diseases — especially regarding how deeply and how long cells get depleted, cytokine release, and giving doses repeatedly? Thanks, we appreciate it.
That's an excellent question. You've pointed to the key considerations for cell depleters employed in autoimmunity, I'd say. What's desired is profound depletion, a product that's safe, a product that's tolerable. Every one of those factors comes into play; beyond that, it hinges on the target and the precise use case; so absent a discussion of those specifics, providing you with a highly detailed response to that specific question isn't something I could do.
Hi there, good afternoon, and I appreciate you taking my question. I have one regarding ABCL635. Would you be able to share what you anticipate for the placebo group in the phase II? Do the small molecule studies serve as a reliable reference point for what the placebo might show? Could you also address which elements of the phase II trial design were included specifically to lessen placebo effects? Thank you.
Every trial conducted so far has demonstrated a substantial placebo effect. Consequently, as we enter this study, we expect a placebo effect will appear as well, and that it will fall within a range similar to what has previously been observed. That is the hypothesis we are operating under. We should find out quite soon, once the data are read out. Regarding efforts to lessen that effect, beyond solid clinical operations, incorporating a period during which patients are being enrolled, without disclosing to them the exact figures required prior to their enrollment — all of those measures are in place. Our confidence in the execution is high. I believe one of the major unknowns is precisely what level that placebo effect will reach. We will have that answer before long. Thanks for the question.
Thanks for fielding our questions, team. We might have one more regarding ABCL635. To start off, can you verify whether the phase II efficacy results will be available at four weeks for every patient, or might there be some patients with data extending to 12 weeks? Just want to get that clarified. Next, regarding the commercial potential in VMS, what are your thoughts on a possible phase III concerning the patient population you'd target? Specifically, do you view this purely as a non-hormonal option, or might you explore a head-to-head comparison in a pivotal trial involving patients who are either currently on HRT or have not responded to it? I'm just attempting to figure out the right way to break that market into segments. Thanks.
The first set of data we expect to get soon will span four weeks for each patient, and we won't be putting out results from a subset of patients who were tracked through twelve weeks. That's what makes up the top-line data. When you look back at efficacy outcomes, there's been a very reliable pattern connecting the four-week numbers to the twelve-week ones; we have strong confidence that our position is a good one; I'd also like to point out that the phase II trial involved just one dose of ABCL635. A component of the trial involves no further dosing, and with the dose decreasing, an effective dose response curve is emerging; by week 12, we'd anticipate the effect to be clearly reduced, though we'll confirm that upon release. Regarding the phase III, I believe discussing the design now is somewhat premature. How precisely you structure this is a fair question, and it really comes down to the medical need. Our view is that, at minimum, a substantial population of women have contraindications and would gain from a non-hormonal choice. As I've mentioned during earlier calls, our estimate is that this figure is approximately, or likely exceeds, 1 million women within the U.S. by itself. Beyond that, a very considerable group of individuals could benefit from a therapy for hot flashes tied to cancer treatment, in which hormones cannot be used. This would encompass prostate cancer as well as breast cancer. Some subset will either not tolerate HRT or choose against it, and that threshold shifts somewhat nowadays, but we see a significant opportunity in that area too. All of this will be factored in once the data arrives, and preparations for the larger trial are underway.
Got it. Appreciate it, everyone.
Hello. Thank you for taking my question, and congratulations on the progress made with the trial. I'm wondering whether you might share any further detail regarding the blinded safety data coming out of the study. When you look at things on a blinded basis, are the general adverse event rates, along with any possible discontinuation rates, coming in as you'd expect? I have one quick follow-up.
Beyond what we shared on the previous call, no safety data has been disclosed. What I can tell you is that nothing observed so far has caused us any hesitation or undermined our thesis, though naturally we'll hold off until unblinding and then examine it carefully. Things remain on track at this point.
Thank you. I appreciate that. Just one more quick question. What is your most current view on the argument over whether hitting the medial preoptic nucleus — having NK3R receptors inhibited in that location — is essential for achieving possible benefit, as opposed to merely suppressing the KNDy neurons located in the arcuate nucleus?
That's an excellent question, and I believe we've brought it up during previous calls. It represents the primary scientific risk that still remains for this program. What I can tell you is that the phase I results we shared during the most recent call demonstrate our ability to achieve profound testosterone suppression, and to accomplish that more deeply than what the small molecules have shown, with that effect persisting across the whole dosing interval. That carries straight through to the KNDy neurons within the infundibular nucleus. Those are thought to be the neurons that matter most. I believe that's something everyone would accept. Looking at it that way, if those turn out to be the sole neurons of consequence, then we'd anticipate an effective drug — and likely one with even superior efficacy compared to what the small molecules have demonstrated, since the testosterone suppression has been larger. What hasn't been settled is whether blocking NK3R in the preoptic nucleus additionally plays a role. We haven't run a definitive preclinical study to establish that. The study that will establish it is the phase II readout, which we expect shortly. That's what's still outstanding. I won't go any further into speculation, but we feel quite confident that we're achieving strong target engagement in the neurons that serve as the primary drivers here. Whether or not an additional attempt at the preoptic nucleus turns out to be important is something we will learn very soon.
Thanks a lot.
I appreciate all of you being on today's call. AbCellera is entering a truly thrilling period. We're eager to bring you updates before long regarding both our pipeline and our portfolio. Thanks.
This concludes today's call. Thank you for attending. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete AbCellera Biologics Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to AbCellera Biologics Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.